Clinical Trial Update: Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing continuous vs intermittent dabrafenib plus trametinib in BRAFV600-mutant unresectable/metastatic melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Melanoma | Phase 2 | Status: COMPLETED